---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-046010"
form_type: "8-K"
ticker: null
cik: "0000811240"
company_name: "BIOLASE, INC"
filed_at: "2024-04-19T23:59:59+00:00"
generated_at: "2026-06-03T17:40:26.923510+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BIOLASE receives Nasdaq delisting notice for bid price non-compliance; hearing requested

## Summary
- Received Nasdaq Staff Letter on April 15, 2024, for failing $1.00 minimum bid price for 30 consecutive business days through March 1, 2024.
- Ineligible for automatic compliance period due to prior panel monitor (Aug 14, 2023) and reverse stock splits exceeding 250:1 cumulative over two years.
- Company will request a hearing before Nasdaq Hearings Panel; request automatically stays suspension/delisting pending hearing and panel decision.
- Panel may grant extension of compliance period up to October 14, 2024. Prior letter of March 4, 2024 was issued in error.

## SEC filing metadata
- accession: 0000950170-24-046010
- form_type: 8-K
- cik: 0000811240
- company_name: BIOLASE, INC
- filed_at: 2024-04-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811240/000095017024046010/0000950170-24-046010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811240/000095017024046010/biol-20240419.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-046010
- JSON: https://secwatch.observer/filing/0000950170-24-046010.json
- Plain text: https://secwatch.observer/filing/0000950170-24-046010.txt

## Key facts
- Listing & Compliance Notices
  BIOLASE, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: April 15, 2024, BIOLASE, Inc. (the “Company”) received a staff determination letter (the “Staff Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC notifying the Company that, unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”), its securities could be subject to suspension from trading on The Nasdaq Capital Market for failure to meet the $1.00 minimum closing bid price requirement for the 30 consecutive business days from January 19 through March 1, 2024, as required by Listing Rule 5550(a)(2), and that the Com
  evidence_url: https://www.sec.gov/Archives/edgar/data/811240/000095017024046010/0000950170-24-046010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.